Regeneron Pharmaceuticals (REGN) Peer Comparison
$813.27
$-2.83
(-0.35%)
As on 28-Oct-2026 16:01EDT
Market cap
$82,881 Mln
Revenue (TTM)
$15,535 Mln
P/E Ratio
19.9
P/B Ratio
2.5
Div. Yield
0.4 %
Edit
| Regeneron Pharmaceuticals (REGN) | Vertex Pharmaceuticals (VRTX) | Moderna (MRNA) | IQVIA Holdings (IQV) | Revolution Medicines (RVMD) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
82,881 | 132,796 | 79,887 | 45,811 | 40,079 |
Revenue ($ Mln) |
15,535 | 12,624 | 2,228 | 16,983 | -- |
Net Profit ($ Mln) |
4,328.70 | 4,405.20 | -3,151.00 | 1,375.00 | -1,768.29 |
Net Margin (%) |
27.86 | 34.89 | -141.43 | 8.10 | -- |
RoE (%) |
13.75 | 22.64 | -40.89 | 21.63 | -83.46 |
Price to Earnings |
19.91 | 29.90 | -- | 34.57 | -- |
Price-To-Book |
2.54 | 6.46 | 9.33 | 7.14 | 16.11 |
Income Statement ($ Mln)
| Regeneron Pharmaceuticals (REGN) | Vertex Pharmaceuticals (VRTX) | Moderna (MRNA) | IQVIA Holdings (IQV) | Revolution Medicines (RVMD) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
15,534.70 | 12,624.30 | 2,228.00 | 16,983.00 | 0.00 |
|
Cost of Revenue
|
2,352.10 | 1,762.80 | 2,508.00 | 12,528.00 | 9.24 |
|
Gross Profit
|
12,242.20 | 10,267.50 | 1,076.00 | 5,430.00 | -16.56 |
|
Operating Expenses
|
9,212.50 | 5,989.90 | 3,040.00 | 2,150.00 | 1,618.01 |
|
Operating Profit (EBIT)
|
3,970.10 | 4,872.00 | -3,320.00 | 2,305.00 | -1,627.25 |
|
Other Income
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Profit before Tax
|
5,166.00 | 5,274.90 | -3,087.00 | 1,609.00 | -1,768.29 |
|
Provision for Tax
|
837.30 | 869.30 | 64.00 | 253.00 | 0.00 |
|
Profit after Tax (Net Income)
|
4,328.70 | 4,405.20 | -3,151.00 | 1,375.00 | -1,768.29 |
|
Minority Interest
|
0.00 | 0.00 | 0.00 | -4.00 | 0.00 |
|
Consolidated Profit
|
0.00 | 0.00 | 0.00 | 845.00 | 0.00 |
Liabilities ($ Mln)
| Regeneron Pharmaceuticals (REGN) | Vertex Pharmaceuticals (VRTX) | Moderna (MRNA) | IQVIA Holdings (IQV) | Revolution Medicines (RVMD) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
31,711.00 | 20,247.90 | 6,761.00 | 6,171.00 | 2,606.24 |
|
Minority Interest
|
0.00 | 0.00 | 0.00 | -4.00 | 0.00 |
|
Non-Current Liabilities
|
4,488.60 | 3,237.50 | 1,666.00 | 14,765.00 | 1,362.97 |
|
Current Liabilities
|
5,530.60 | 3,937.90 | 2,534.00 | 8,815.00 | 354.06 |
|
Total Liabilities
|
40,558.70 | 26,142.80 | 12,338.00 | 29,944.00 | 2,354.51 |
Assets ($ Mln)
| Regeneron Pharmaceuticals (REGN) | Vertex Pharmaceuticals (VRTX) | Moderna (MRNA) | IQVIA Holdings (IQV) | Revolution Medicines (RVMD) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
23,284.00 | 14,879.60 | 5,146.00 | 23,655.00 | 294.93 |
|
Current Assets
|
18,446.00 | 12,543.70 | 5,815.00 | 6,226.00 | 4,028.34 |
|
Total Assets
|
40,558.70 | 26,142.80 | 12,338.00 | 29,944.00 | 2,354.51 |
|
Total Debt*
|
1,986.60 | 1,977.60 | 1,287.00 | 16,241.00 | 641.93 |
|
Net Current Assets
|
12,915.40 | 8,605.80 | 3,281.00 | -2,589.00 | 3,674.28 |
Cashflow ($ Mln)
| Regeneron Pharmaceuticals (REGN) | Vertex Pharmaceuticals (VRTX) | Moderna (MRNA) | IQVIA Holdings (IQV) | Revolution Medicines (RVMD) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
4,978.90 | 3,631.40 | -1,873.00 | 2,654.00 | -897.74 |
|
Cash Flow from Investing Activities
|
-629.10 | -945.40 | 1,946.00 | -2,305.00 | 118.06 |
|
Cash from Financing Activities
|
-3,715.40 | -2,261.30 | 593.00 | -150.00 | 621.52 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Regeneron Pharmaceuticals (REGN) | Vertex Pharmaceuticals (VRTX) | Moderna (MRNA) | IQVIA Holdings (IQV) | Revolution Medicines (RVMD) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
13.65 | 19.42 | -25.41 | 6.34 | -53.99 |
|
ROE (%)
|
13.75 | 22.64 | -40.89 | 21.63 | -83.46 |
|
ROA (%)
|
9.71 | 14.80 | -23.27 | 3.67 | -48.50 |
|
EBIT Margin (%)
|
33.61 | 41.84 | -137.79 | 13.81 | -- |
|
Net Margin (%)
|
27.86 | 34.89 | -141.43 | 8.10 | -- |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | -- |
Growth Ratios
| Regeneron Pharmaceuticals (REGN) | Vertex Pharmaceuticals (VRTX) | Moderna (MRNA) | IQVIA Holdings (IQV) | Revolution Medicines (RVMD) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
9.29 | 10.56 | -27.19 | 8.17 | -- |
|
EBIT Growth (%)
|
6.31 | 20.32 | -4.74 | 5.30 | -110.25 |
|
Net Profit Growth (%)
|
-2.91 | 21.10 | -8.54 | 11.16 | -117.75 |
|
EPS Growth (%)
|
1.72 | 22.80 | -6.34 | 16.60 | -95.21 |
|
Book Value Growth (%)
|
7.70 | 19.36 | -29.52 | 9.72 | 24.65 |
Valuation Ratios
| Regeneron Pharmaceuticals (REGN) | Vertex Pharmaceuticals (VRTX) | Moderna (MRNA) | IQVIA Holdings (IQV) | Revolution Medicines (RVMD) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
18.42 | 29.37 | -4.10 | 28.49 | -13.39 |
|
Price / Book Value
|
2.65 | 6.22 | 1.34 | 5.96 | 9.28 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
13.25 | 23.30 | -3.01 | 17.96 | -12.17 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Regeneron Pharmaceuticals (REGN) | Vertex Pharmaceuticals (VRTX) | Moderna (MRNA) | IQVIA Holdings (IQV) | Revolution Medicines (RVMD) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.06 | 0.00 | 0.09 | 2.22 | 0.19 |
|
Short term debt to equity ratio
|
0.00 | 0.00 | 0.01 | 0.37 | 0.01 |
|
Current Ratio
|
3.34 | 3.19 | 2.29 | 0.71 | 11.38 |
|
Quick Ratio
|
2.78 | 2.74 | 2.18 | 0.71 | 11.38 |
|
Interest Coverage
|
94.25 | 800.23 | -72.50 | 3.09 | -28.80 |
Operating Efficiency Ratios
| Regeneron Pharmaceuticals (REGN) | Vertex Pharmaceuticals (VRTX) | Moderna (MRNA) | IQVIA Holdings (IQV) | Revolution Medicines (RVMD) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
42.26 | 16.91 | 4.62 | 19.94 | -- |
|
Asset Turnover
|
0.35 | 0.42 | 0.16 | 0.45 | 0.00 |
|
Receivable days
|
152.19 | 55.39 | 82.29 | 74.65 | -- |
|
Inventory Days
|
546.66 | 292.28 | 56.81 | -- | -- |
|
Payable days
|
150.27 | 88.40 | 151.91 | 75.32 | 1,312.97 |
|
Cash Conversion Cycle
|
548.59 | 259.28 | -12.81 | -- | -- |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
